Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

BACKGROUND & AIMS: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH....

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Mukul R., Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Ranvir, Ramchandra, Kadam, Shekhar, Patel, Hiren, Swain, Prabodha, Roy, Sib Sankar, Das, Nabanita, Karmakar, Eshani, Wahli, Walter, Patel, Pankaj R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Genetic and Metabolic Liver Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001453/
https://www.ncbi.nlm.nih.gov/pubmed/29164820
http://dx.doi.org/10.1111/liv.13634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001453/
https://www.ncbi.nlm.nih.gov/pubmed/29164820
http://dx.doi.org/10.1111/liv.13634

Ejemplares similares